2024
Precision needle-punch tumor enrichment from paraffin blocks improves the detection of clinically actionable genomic alterations and biomarkers
Lin D, Huang R, Ladas I, Keller R, Patel N, Lakis S, Decker B, Janovitz T, Mata D, Ross J, Vergilio J, Elvin J, Herbst R, Mack P, Killian J. Precision needle-punch tumor enrichment from paraffin blocks improves the detection of clinically actionable genomic alterations and biomarkers. Frontiers In Oncology 2024, 14: 1328512. PMID: 38444675, PMCID: PMC10912171, DOI: 10.3389/fonc.2024.1328512.Peer-Reviewed Original ResearchTumor mutational burdenTumor purityTumor specimensNext-generation sequencingClinically actionable genomic alterationsMicrosatellite instabilityBiomarker statusTissue-conserving methodTissue blocksHigh tumor purityLow tumor purityComplex biomarkersSurgical pathology materialClinical samplesClinical trial enrollmentVariant allele frequencyResidual tumorMutational burdenTumor enrichmentTumor contentTumor cellsGenomic alterationsFormalin-fixedParaffin blocksDetect mutations
2013
Retrospective evaluation of RET biomarker status and outcome to vandetanib in four phase III randomized NSCLC trials.
Platt A, Elvin P, Morten J, Ji Q, Donald E, Womack C, Su X, Zheng L, Gladwin A, Vasselli J, Lee J, De Boer R, Herbst R. Retrospective evaluation of RET biomarker status and outcome to vandetanib in four phase III randomized NSCLC trials. Journal Of Clinical Oncology 2013, 31: 8045-8045. DOI: 10.1200/jco.2013.31.15_suppl.8045.Peer-Reviewed Original ResearchRET fusionsNSCLC trialsTumor samplesRET fusion genesFusion-positive patientsGene copy number gainRET protein expressionRECIST responseRadiologic evidenceEvaluable dataTumor shrinkageNSCLC tumorsBiomarker statusIHC analysisCopy number gainsRET amplificationRetrospective evaluationPatientsPotential associationVandetanibRET expressionPrevalenceProtein expressionPhase IIIBiomarkers
2010
Sorafenib treatment efficacy and KRAS biomarker status in the Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) trial.
Herbst R, Blumenschein G, Kim E, Lee J, Tsao A, Alden C, Liu S, Stewart D, Wistuba I, Hong W. Sorafenib treatment efficacy and KRAS biomarker status in the Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) trial. Journal Of Clinical Oncology 2010, 28: 7609-7609. DOI: 10.1200/jco.2010.28.15_suppl.7609.Peer-Reviewed Original Research